ADAP - Adaptimmune Therapeutics plc
8.47 0.00 (0.00%)
After hours: 5:13PM EDT
| Previous Close | 8.27 |
| Open | 8.25 |
| Bid | 8.00 x 800 |
| Ask | 8.68 x 1100 |
| Day's Range | 8.25 - 8.52 |
| 52 Week Range | 4.84 - 14.62 |
| Volume | 221,511 |
| Avg. Volume | 391,343 |
| Market Cap | 799.704M |
| Beta | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.71 |
- GlobeNewswire•yesterday
Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NEXEO ...
- GlobeNewswire•6 days ago
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
PHILADELPHIA and OXFORD, United Kingdom, Aug. 15, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose ...
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT
Q2 2018 Adaptimmune Therapeutics PLC Earnings Call
- GlobeNewswire•19 days ago
Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
-Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells-. -NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets-. -Guidance confirmed, ...
- ACCESSWIRE•20 days ago
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adaptimmune Therapeutics PLC Sponsored ADR (NASDAQ: ADAP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 ...
- GlobeNewswire•26 days ago
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide ...
- American City Business Journals•28 days ago
Why AdaptImmune collected $27.5M from GSK
Adaptimmune received a $27.5 million payment from GlaxoSmithKline following the transitioning of a T-cell therapy program targeted solid tumors from one company to the other. As a result of the transition, GSK has assumed full responsibility for the future research, development, and potential commercialization of Adaptimmune's NY-ESO SPEAR T-cell therapy being looked as a potential treatment for a variety of cancers including non-small cell lung cancer, metastatic melanoma, ovarian and multiple myeloma. Adaptimmune's NY-ESO SPEAR T-cell therapy technology is designed to boost the ability of a person’s own immune system to recognize and destroy cancer cells.
- GlobeNewswire•28 days ago
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
LONDON and OXFORD, United Kingdom, July 24, 2018-- GlaxoSmithKline plc and Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the transition of the development program ...
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...
- GlobeNewswire•last month
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort ...
- Simply Wall St.•2 months ago
Investors Are Undervaluing Adaptimmune Therapeutics plc (NASDAQ:ADAP) By 21.72%
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Adaptimmune Therapeutics plc (NASDAQ:ADAP) as an investment opportunity by projecting itsRead More...
- GlobeNewswire•2 months ago
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that data from the pilot study of NY-ESO SPEAR T‑ cells ...
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
- GlobeNewswire•3 months ago
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
-Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts-. -Dosing continues with the one billion“ target” cell dose-. PHILADELPHIA, Pa. and OXFORD, U.K., June ...
- GlobeNewswire•3 months ago
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
-No evidence of off-target toxicity at 100 million cells for second wholly owned asset-. -Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 basket study-. PHILADELPHIA, ...
- GlobeNewswire•3 months ago
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2018-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, presented initial data from the ongoing pilot study of NY-ESO SPEAR T-cells ...
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol — Discovering Underlying Factors of Influence
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK ...
- CNBC•3 months ago
Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Clorox : "Clorox is caught up in this whole vortex of the 10-year Treasury going above 3 percent yield.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ADAP earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Adaptimmune Therapeutics PLC Earnings Call
- ACCESSWIRE•3 months ago
Wired News – VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine
LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VBIV as the Company's latest news hit the wire. On May 10, 2018, the commercial-stage biopharmaceutical Company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology, reported positive results from the randomized, placebo-controlled Phase-1 study of VBI-1501. Active-Investors.com is currently working on the research report for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), which also belongs to the Healthcare sector as the Company VBI Vaccines.
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- CNBC Videos•3 months ago
Cramer's lightning round: Take a pass on Bristol-Myers Sq...
Jim Cramer fires off his take on callers' favorite stocks, including a biopharmaceutical play facing a rival.
